Efficacy and Safety of Empagliflozin (EMPA) in Younger, Overweight/Obese Patients with Type 2 Diabetes (T2DM) with HbA1c ≥8%

被引：0
|
作者：
Merker, Ludwig
Lund, Soren S.
Hantel, Stefan
Salsali, Afshin
Kim, Gabriel
Broedl, Uli C.
Woerle, Hans J.
Hach, Thomas
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1079-P
引用
收藏
页码：A280 / A281
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of empagliflozin in younger overweight/obese patients with Type 2 diabetes with HbA1c ≥8%
    Merker, L.
    Lund, S. S.
    Hantel, S.
    Salsali, A.
    Kim, G.
    Broedl, U. C.
    Woerle, H. J.
    Hach, T.
    DIABETIC MEDICINE, 2015, 32 : 90 - 90
  • [2] HbA1c Response to Open-Label (OL) Empagliflozin (EMPA) with Metformin (MET) in Patients with Type 2 Diabetes (T2DM)
    Schernthaner, Guntram
    Tinahones, Francisco J.
    Goetz, Sophia
    Lee, Christopher
    DIABETES, 2017, 66 : A345 - A346
  • [3] Consistent Weight Changes Irrespective of Baseline HbA1c with the Combination of Empagliflozin/Linagliptin (EMPA/LINA) in Subjects with Type 2 Diabetes (T2DM)
    Barnett, Anthony H.
    Defronzo, Ralph A.
    Lewin, Andrew
    Patel, Sanjay
    Liu, Dacheng
    Kaste, Renee
    Broedl, Uli C.
    Lee, Christopher
    DIABETES, 2015, 64 : A656 - A656
  • [4] Effect of empagliflozin (EMPA) on bone fractures in patients with type 2 diabetes (T2DM)
    Kohler, S.
    Kaspers, S.
    Salsali, A.
    Zeller, C.
    Woerle, H. -J.
    DIABETOLOGIA, 2016, 59 : S26 - S26
  • [5] Modelling HbA1c Trajectory in Patients with Type 2 Diabetes Mellitus (T2DM)
    Mcewan, Phil
    Fellows, Jonathan
    Yapp, Rhiannon
    Bergenheim, Klas
    Qin, Lei
    Varol, Nebibe
    Bennett, Hayley
    Gordon, Jason
    DIABETES, 2016, 65 : A322 - A322
  • [6] Treatment Progression and Impact of HbA1C in Type 2 Diabetes (T2DM) Patients
    Dibello, Julia R.
    Levy, Brian
    Mehra, Maneesha
    DIABETES, 2010, 59 : A623 - A624
  • [7] Safety and tolerability of empagliflozin (EMPA) in phase III trials and their extensions in patients with type 2 diabetes (T2DM)
    Roden, M.
    Merker, L.
    Christiansen, A. V.
    Roux, F.
    Hantel, S.
    Salsali, A.
    Kim, G.
    Meinicke, T.
    Lund, S. S.
    Hach, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETOLOGIA, 2014, 57 : S325 - S326
  • [8] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes (T2DM)
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2015, 64 : A302 - A303
  • [9] HbA1c and Prediction of Type 2 Diabetes (T2DM) in Children and Adults
    Vijayakumar, Pavithra
    Nelson, Robert G.
    Hanson, Robert L.
    Knowler, William C.
    Sinha, Madhumita
    DIABETES, 2016, 65 : A65 - A65
  • [10] Slope of Decline in HbA1c with Empagliflozin Appears to Be Greater than the Slope with Sitagliptin or Glimepiride in Patients with Type 2 Diabetes (T2DM)
    Defronzo, Ralph A.
    Elsasser, Ulrich
    Lund, Soren S.
    Hach, Thomas
    DIABETES, 2015, 64 : A331 - A332
12345